# Eli Lilly (incl. Loxo)

Source: https://nuclide.cc/companies/eli-lilly/  
Nuclide record `eli-lilly` (Company). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

Eli Lilly makes Verzenio and Retevmo, as well as the oral SERD imlunestrant and the BTK inhibitor pirtobrutinib.

## Summary

Eli Lilly, based in Indianapolis and listed as LLY, makes Verzenio and Retevmo, the oral SERD imlunestrant and the BTK inhibitor pirtobrutinib, and its oncology unit includes Loxo Oncology. The portfolio spans abemaciclib, selpercatinib, imlunestrant, sold as Inluriyo from 2025, pirtobrutinib, olomorasib against KRAS G12C, a PI3K-alpha mutant-selective programme from Scorpion, and older products including cetuximab, gemcitabine and necitumumab. Nuclide links it to the monarchE paper on two years of adjuvant abemaciclib, to CLEAR in kidney cancer, to GLP-1 receptor agonists and obesity-related cancer risk, to ideas for trials of GLP-1 drugs with cancer as the primary outcome, and to partners including Isomorphic Labs and Innovent. Whether Lilly's GLP-1 franchise becomes an oncology story is the question its idea links raise. Abemaciclib and selpercatinib have their own pages.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- HQ: Indianapolis, IN
- Type: pharma
- Website: https://www.lilly.com
- Ticker: LLY

## Sources

- Official website: https://www.lilly.com

## Connected records

- companies: [POINT Biopharma](https://nuclide.cc/companies/point-biopharma/)
- indications: [Hepatocellular carcinoma](https://nuclide.cc/indications/hcc/), [Multiple endocrine neoplasia syndromes (MEN1, MEN2, MEN4)](https://nuclide.cc/indications/multiple-endocrine-neoplasia/), [Thyroid cancer](https://nuclide.cc/indications/thyroid/)
- drugs: [Florbetapir F-18](https://nuclide.cc/drugs/f-18-florbetapir/), [Flortaucipir F-18](https://nuclide.cc/drugs/f-18-flortaucipir/), [Lutetium-177 PNT2002](https://nuclide.cc/drugs/lu-177-pnt2002/)

---
JSON: https://nuclide.cc/api/v1/entities/eli-lilly.json